Quotables
"If you build a better mousetrap, you will catch better mice."
George Gobel
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7598379 | Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines The present invention provides processes for making pyridyl-linked-xanthines of formula VII, from 5,6-diamino-1H-pyrimidine-2,4-diones of formula II and acylating agents of formula VI. The xanthines are expected to be are sel... | 10/06/2009 |
| 7425560 | Thioxanthine derivatives as myeloperoxidase inhibitors There is disclosed the use of a compound of formula (Ia) or (Ib) wherein R1, R2, R3, R4, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament, for t... | 09/16/2008 |
| 7423041 | A1 adenosine receptor antagonists Compounds of the general formula (I) are described: wherein A is a 5- or 6-membered aromatic or heteroaromatic ring. Compositions comprising such compounds and methods of use thereof are also described. ... | 09/09/2008 |
| 7407955 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions The present invention relates to substituted xanthines of general formula wherein R1 to R3 are defined as in claims 1 to 16, the tautomers, the stereoisomers, the mixtures, the prodrugs t... | 08/05/2008 |
| 7342006 | Substituted 8-heteroaryl xanthines Selective antagonists of A2B adenosine receptors like those of formula I are provide. The compounds and compositions are useful as pharmaceutical agents. ... | 03/11/2008 |
| 7317017 | Aadenosine receptor antagonists Disclosed are novel A2B adenosine receptor antagonists having the structure of Formula I or Formula II The compounds are particularly useful for treating asthma, inflammatory gastrointestinal tract dis... | 01/08/2008 |
| 7307166 | Oxpurine nucleosides and their congeners, and acyl, derivatives thereof, for improvement of hematopoiesis The invention relates to certain oxypurine nucleosides, congeners of such oxypurine nucleosides, and acyl derivatives thereof, and compositions which contain at least one of these compounds. The invention also relates to methods of treating or preventing hematopoiet... | 12/11/2007 |
| 7304070 | Aadenosine receptor antagonists Disclosed are novel A2B adenosine receptor antagonists having the structure of Formula I or Formula II: The compounds are particularly useful for treating asthma, inflammatory gastrointestinal tract di... | 12/04/2007 |
| 7268141 | Xanthine phosphodiesterase V inhibitors A xanthine phosphodiesterase V inhibitor having the formula (I), with the variables defined herein, which is especially useful for treating male (erectile) and female sexual dysfunction and other physiological disorders: | 09/11/2007 |
| 7268145 | Thiobenzimidazole derivatives The present invention is a thiobenzimidazole derivative represented by the following formula (1) or a medically acceptable salt thereof wherein said thiobenzimidazole derivative and a medically acceptable salt th... | 09/11/2007 |
| 7247639 | A1 adenosine receptor antagonists The present invention provides novel adenosine receptor antagonists, more particularly, A1 adenosine receptor antagonists of formula (I). Pharmaceutical compositions comprising an A1 adenosine receptor antagonist of formula (I) and a pharmaceut... | 07/24/2007 |
| 7235538 | Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV The present invention relates to therapeutically active and selective inhibitors of the enzyme DPP-IV, which are of formula I wherein each n is one or two independently and R1, R2, R3 | 06/26/2007 |
| 7205403 | 8-Heteroaryl xanthine adenosine Areceptor antagonists The present invention relates generally to compounds of the formula (I): wherein: X is a five or six-membered heteroaromatic ring, containing one to four heteroatoms, selected f... | 04/17/2007 |
| 7202252 | Aadenosine receptor antagonists Compounds of the general formula (I) are described: wherein A is a 5- or 6-membered aromatic or heteroaromatic ring. Compositions comprising such compounds and methods of use thereof are also described. ... | 04/10/2007 |
| 7192952 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV The present invention relates to therapeutically active and selective inhibitors of the enzyme DPP-IV of formula I, pharmaceutical compositions comprising the compounds and the use of such compounds for and the manufacture of medicaments for treating diseases that a... | 03/20/2007 |
| 7148229 | Sulfonamide substituted xanthine derivatives The present invention is a sulfonamide substituted xanthine derivative of formula I: or a pharmaceutically acceptable salt thereof, wherein R1 is lower alkyl, lower alkyl substituted by phenyl, or lower alkyl sub... | 12/12/2006 |
| 7135475 | Amide substituted xanthine derivatives The present invention is a 1,3,8 substituted xanthine derivative of formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are as defined in the specificat... | 11/14/2006 |
| 7125993 | Aadenosine receptor antagonists Disclosed are processes for the synthesis of novel compounds that are A2B adenosine receptor antagonists, having the structure of Formula I or Formula II: by cyclizing a compound of the formula (3): | 10/24/2006 |
| 7105665 | Aadenosine receptor antagonists Disclosed are methods for making novel A2B adenosine receptor antagonists having the structure of formula I or Formula II: The compounds are particularly useful for treating asthma, inflammatory gastro... | 09/12/2006 |
| 7053096 | Compounds having selective hydrolytic potentials Disclosed are compounds having selective hydrolytic potential. The disclosed compounds are useful as compounds having selective stability and are capable of undergoing programmed hydrolysis in biologic systems. ... | 05/30/2006 |
| 6977300 | A2B adenosine receptor antagonists Disclosed are novel A2B adenosine receptor antagonists having the structure of Formula I or Formula II: The compounds are particularly useful for treating asthma, inflammatory gastrointestinal tract disorder... | 12/20/2005 |
| 6869947 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV The present invention relates to therapeutically active and selective inhibitors of the enzyme DPP-IV of formula I, pharmaceutical compositions comprising the compounds and the use of such compounds for and the manufacture of medicaments for treating diseases that a... | 03/22/2005 |
| 6846833 | Vitronectin receptor antagonist bicyclic compounds, preparation method and compositions containing same Compounds of formula (1): wherein: G represents an optionally substituted phenyl or optionally substituted heterocycle, G1 and G2 being N or C, ... | 01/25/2005 |
| 6825349 | A2B adenosine receptor antagonists Disclosed are novel A2B adenosine receptor antagonists compounds having the structure of Formula I or Formula II: The compounds are particularly useful for treating asthma, inflammatory gastrointestinal trac... | 11/30/2004 |
| 6780865 | Compounds having selective hydrolytic potentials Disclosed are compounds having selective hydrolytic potential. The disclosed compounds are useful as compounds having selective stability and are capable of undergoing programmed hydrolysis in biologic systems. The disclosed compounds have a structure of formula I: ... | 08/24/2004 |
| 6774130 | Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same Novel heterocyclic compounds having a six membered ring structure fused to a five membered ring structure are found to be useful for the treatment and prevention of symptoms or manifestations associated with disorders affected by Interleukin-12 (“IL-12”) intrace... | 08/10/2004 |
| 6734187 | Purine derivatives and medicaments comprising the same as active ingredient Purine derivatives represented by the following formula and salts thereof: wherein R1 represents a C1-C4 alkyl group or difluoromethyl group; R2 represents tetrahydrofuranyl gr... | 05/11/2004 |
| 6723727 | Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them The present invention relates to compounds of the formulae I and Ia in which X, Y, W, Wa, G and Ga have the meanings given in the patent claims, and their physiologically tolerable salts and their p... | 04/20/2004 |
| 6716961 | Chiral peptide nucleic acids with a N-aminoethyl-d-proline backbone Chiral peptide nucleic acids are provided which hybridise strongly with complementary nucleic acids and have potential as antigene and antisense agents and as tools in molecular biology. The compounds have the formulae. ... | 04/06/2004 |
| 6706892 | Pulmonary delivery for bioconjugation Methods of and compositions for pulmonary delivery of therapeutic agents which are capable of forming covalent bonds with a site of interest or which have formed a covalent bond with a pulmonary solution protein are disclosed. Therapeutic agents useful in the invent... | 03/16/2004 |
| 6653312 | Amidine derivatives, their preparation and application as medicines and pharmaceutical compositions containing same Amidine compounds of the formula ##STR1## wherein the substituents are defined as in the application useful as NO-synthase enzyme inhibitors.... | 11/25/2003 |
| 6608069 | Phenyl xanthine derivatives The present invention relates to novel compounds of formula (I): ##STR1## wherein Z represents a 5 or 6 membered cycloalkyl, aryl, substituted cycloalkyl, or substituted aryl, said cycloalkyl, aryl, substituted cycloalkyl or substituted aryl optionally co... | 08/19/2003 |
| 6545002 | Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors The present invention provides compounds having the formula I: ##STR1## X is (C1 -C8)alkylene, (C2 -C8)alkenylene, (C2 -C8)alkynylene, wherein one of the carbon atoms in the alkylene, alken... | 04/08/2003 |
| 6518425 | Method of manufacture of 1,3-oxathiolane nucleosides Processes for the preparation of 1,3-oxathiolane nucleosides are provided that include efficient methods for the preparation of the 1,3-oxathiolane ring and subsequent condensation of the 1,3-oxathiolane with a pyrimidine or purine base. Using the process... | 02/11/2003 |
| 6258809 | 6-aryloxy and arylthiopurines Novel compounds and pharmaceutical compositions thereof, and methods of using same in treating anxiety, depression, and other psychiatric and neurological disorders. The novel compounds provided by this invention are those of the following formulae: ... | 07/10/2001 |
| 6248746 | 3-(arylalkyl) xanthines With the above and other objects in view, the present invention comprises compounds having the general formula (I): ##STR1## wherein: R1 is a C2-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 cycloalkyl, C... | 06/19/2001 |
| 6221874 | Method of treating bone loss by stimulation of calcitonin Compounds of the formula ##STR1## R1 and R2 are independently alkyl of 1 to 6 carbon atoms, allyl, or substituted allyl of 3 to 6 carbon atoms; R3 is hydrogen, alkyl of 1 to 6 carbon atoms, or cycloalkyl of 3 to 10 carbon ... | 04/24/2001 |
| 6175008 | Processes for preparing substituted 1,3-oxathiolanes with antiviral properties Disclosed are processes for preparing compounds of the formula (I) and pharmaceutically acceptable salts or esters thereof: ##STR1## wherein R2 is a purine or pyrimidine base or an analogue or derivative thereof; and Z is S, S.dbd.O or SO2... | 01/16/2001 |
| 6150532 | Modulators of proteins with phosphotyrosine recognition units The present invention relates to novel protein tyrosine phosphatase modulating compounds having the general structure shown in Formula (A1), to methods for their preparation, to compositions comprising the compounds, to their use for treatment of human an... | 11/21/2000 |
| 6124288 | Xanthines and their therapeutic use The subject invention concerns a compound of the formula (i): ##STR1## in which Q represents heteroaryl or heterocyclo optionally substituted with one or more substituents selected from the group consisting of C1-6 alkyl (optionally substi... | 09/26/2000 |
